P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000846556.04927.df |
| _version_ | 1797281779493634048 |
|---|---|
| author | R. Popat P. Moreau S. Z. Usmani A. Garfall M.-V. Mateos J. F. San-Miguel A. Oriol A. K. Nooka L. Rosinol A. Chari L. Karlin A. Krishnan N. Bahlis T. Martin B. Besemer J. Martínez-López M. Delforge J. Fastenau K. S. Gries N. W. van de Donk |
| author_facet | R. Popat P. Moreau S. Z. Usmani A. Garfall M.-V. Mateos J. F. San-Miguel A. Oriol A. K. Nooka L. Rosinol A. Chari L. Karlin A. Krishnan N. Bahlis T. Martin B. Besemer J. Martínez-López M. Delforge J. Fastenau K. S. Gries N. W. van de Donk |
| author_sort | R. Popat |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:02:22Z |
| format | Article |
| id | doaj.art-e1f43ed7e92443daa647dd3bcbf4d630 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:02:22Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-e1f43ed7e92443daa647dd3bcbf4d6302024-03-03T03:19:41ZengWileyHemaSphere2572-92412022-06-01681281310.1097/01.HS9.0000846556.04927.df202206003-00812P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1R. Popat0P. Moreau1S. Z. Usmani2A. Garfall3M.-V. Mateos4J. F. San-Miguel5A. Oriol6A. K. Nooka7L. Rosinol8A. Chari9L. Karlin10A. Krishnan11N. Bahlis12T. Martin13B. Besemer14J. Martínez-López15M. Delforge16J. Fastenau17K. S. Gries18N. W. van de Donk191 University College London Hospitals, NHS Foundation Trust, London, United Kingdom2 Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France3 Levine Cancer Institute/Atrium Health, Charlotte, NC4 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America5 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca6 Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona7 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain8 Winship Cancer Institute, Emory University, Atlanta, GA, United States of America9 Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain10 Mount Sinai School of Medicine, New York, NY, United States of America11 Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France12 City of Hope Comprehensive Cancer Center, Duarte, CA13 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, CA14 University of California San Francisco, San Francisco, CA, United States of America15 University of Tuebingen, Tuebingen, Germany16 Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, CNIO, CIBERONC, Madrid, Spain17 Universitaire Ziekenhuizen Leuven, Leuven, Belgium18 Janssen Research & Development, Raritan, NJ, United States of America18 Janssen Research & Development, Raritan, NJ, United States of America19 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlandshttp://journals.lww.com/10.1097/01.HS9.0000846556.04927.df |
| spellingShingle | R. Popat P. Moreau S. Z. Usmani A. Garfall M.-V. Mateos J. F. San-Miguel A. Oriol A. K. Nooka L. Rosinol A. Chari L. Karlin A. Krishnan N. Bahlis T. Martin B. Besemer J. Martínez-López M. Delforge J. Fastenau K. S. Gries N. W. van de Donk P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 HemaSphere |
| title | P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title_full | P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title_fullStr | P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title_full_unstemmed | P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title_short | P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title_sort | p922 health related quality of life with teclistamab a b cell maturation antigen x cd3 bispecific antibody in patients with relapsed refractory multiple myeloma from majestec 1 |
| url | http://journals.lww.com/10.1097/01.HS9.0000846556.04927.df |
| work_keys_str_mv | AT rpopat p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT pmoreau p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT szusmani p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT agarfall p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT mvmateos p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT jfsanmiguel p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT aoriol p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT aknooka p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT lrosinol p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT achari p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT lkarlin p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT akrishnan p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT nbahlis p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT tmartin p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT bbesemer p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT jmartinezlopez p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT mdelforge p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT jfastenau p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT ksgries p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT nwvandedonk p922healthrelatedqualityoflifewithteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 |